CA 19-9 as a marker in addition to CEA to monitor colorectal cancer

Clinical Colorectal Cancer

Volumn 13, Issue 4, 2014, Pages 239-244

  Stiksma, Jolanda ^a,b   Grootendorst, Diana C ^a,c   Van Der Linden, Peter Willem G ^a  

^a Department of Orthopaedic Surgery   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MEDICAL CENTER HAAGLANDEN   (Netherlands)

Author keywords

CA19 9; CEA; Follow up; Pre operative; Tumor markers

Indexed keywords

CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; TUMOR MARKER;

ADULT; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; COLORECTAL CANCER; DISEASE COURSE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATIENT MONITORING; PREOPERATIVE PERIOD; RETROSPECTIVE STUDY; AGED; BLOOD; CANCER STAGING; COLORECTAL TUMOR; IMMUNOASSAY; LIVER TUMOR; LUNG TUMOR; LYMPH NODE METASTASIS; PATHOLOGY; PROGNOSIS; SECONDARY; SURVIVAL RATE;

AGED; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; COLORECTAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOASSAY; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84922657457     PISSN: 15330028     EISSN: 19380674     Source Type: Journal    
DOI: 10.1016/j.clcc.2014.09.004     Document Type: Article

References (20)

1. Filella X, Molina R, Grau JJ, et al. Prognostic value of CA 19-9 levels in colorectal cancer. Ann Surg 1992; 216: 55-9.
2. Duffy MJ, Dalen van A, Haglund C, et al. Clinical utility of biochemical markers in colorectal cancer. European Group on Tumor Markers (EGTM) guidelines. Eur J Cancer 2003; 39: 718-27.
3. Hanke B, Riedel C, Lampert S, et al. CEA and CA 19-9 measurement as a monitoring parameter in metastatic colorectal cancer (CRC) under palliative fistline chemotherapy with weekly 24-hour infusion of high-dose 5-fluoracil (5-FU) and folinic acid (FA). Ann Oncol 2001; 12: 221-6.
4. Sajid KM, Parveen R, Durr-e-Sabih, et al. Carcinoembryonic antigen (CEA) levels in hookah smokers, cigarette smokers and non-smokers. J PakMedAssoc 2007; 57: 595-9.
5. Sorbye H, Dahl O. Transient CEA increase at start of oxaliplatin combination therapy for metastatic colorectal cancer. Acta Oncol 2004; 43: 495-8.
6. Li YH, An X, Xiang XJ. Clinical significance of a transient increase in carcinoembryonic antigen and carbohydrate antigen 19-9 in patients with metastatic colorectal cancer receiving chemotherapy [in Chinese]. Ai Zheng 2009; 28: 939-44.
7. Koprowski H, Steplewski Z, Mitchell K, et al. Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet 1979; 5: 957-72.
8. Zheng CX, Zhan WH, Zhoa JZ, et al. The prognostic value of preoperative serum levels of CEA, CA 19-9 and CA 72-4 in patients with colorectal cancer. World J Gastroenterol 2001; 7: 431-4.
9. Thomas WM, Robertson JF, Price MR, Hardcastle JD. Failure of CA 19-9 to detect asymptomatic colorectal carcinoma. Br J Cancer 1991; 63: 975-6.
10. Locker GY, Hamilton S, Harris J, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006; 24: 5313-27.
11. Tempero MA, Uchida E, Takasaki H, et al. Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. Cancer Res 1987; 47: 5501-3.
12. Narimatsu H, Iwasaki H, Nakayama F, et al. Lewis and secretor gene dosage affect CA 19-9 and DU-PAN-2 serum levels in normal individuals and colorectal cancer patients. Cancer Res 1998; 58: 512-8.
13. Wobbes TH, Thomas CM, Segers MF. The value of tumor markers (among which carcinoembryonal antigen) in the diagnosis of malignant tumors in the gastrointestinal tract [in Dutch]. Ned Tijdschr Geneeskd 1993; 137: 995-9.
14. Kawai S, Suzuki K, Nishio K, et al. Smoking and serum CA 19-9 levels according to Lewis and secretor genotypes. Int J Cancer 2008; 123: 2880-4.
15. Reiter W, Stieber P, Reuter C, et al. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer. Anticancer Res 2000; 20: 5195-8.
16. Uygur-Bayramiçli O, Dabak R, Orbay E, et al. Type 2 diabetes mellitus and CA 19-9 levels. World J Gastroenterol 2007; 13: 5357-9.
17. Nakamura N, Aoji O, Yoshikawa t, et al. Elevated serum CA 19-9 levels in poorly controlled diabetes patients. Jpn J Med 1986; 25: 278-80.
18. Del Villano BC, Brenman S, Brock P, et al. Radioimmunometric assay for monoclonal antibody-defined tumor marker CA 19-9. Clin Chem 1983; 29: 549-52.
19. Lindmark G, Bergström R, Påhlman L, Glimelius B. The association of preoperative serum tumour markers with Dukes' stage and survival in colorectal cancer. Br J Cancer 1995; 71: 1090-4.
20. Lochhead P, Kuchiba A, Imamura Y. Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J Natl Cancer Inst 2013; 105: 1151-6.